Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG001 imaging in oral and oropharyngeal squamous cell carcinoma
2022-001361-12Phase 2Completed
- Sponsor
- FluoGuide
- Start
- Jul 2022
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FG001 in Oral Mucosal Carcinoma and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by FluoGuide. Primary endpoint: Sensitivity for detection of oral and oropharyngeal cancer. Started Jul 2022; status: completed.
02
Drugs
FG001
03
Conditions
Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2022-001361-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001361-12.